Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug
暂无分享,去创建一个
[1] J. Baeten,et al. Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis , 2017, Journal of acquired immune deficiency syndromes.
[2] E. Vittinghoff,et al. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project , 2017, Journal of acquired immune deficiency syndromes.
[3] E. Clementi,et al. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF , 2017, Journal of acquired immune deficiency syndromes.
[4] M. Wainberg,et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. , 2017, The lancet. HIV.
[5] D. Fine,et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient , 2017, Medicine.
[6] C. Leen,et al. Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] S. Oka,et al. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1–Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort , 2017, AIDS patient care and STDs.
[8] S. Antinori,et al. Renal function in HIV/HBV co‐infected and HBV mono‐infected patients on a long‐term treatment with tenofovir in real life setting , 2017, Clinical and experimental pharmacology & physiology.
[9] C. Gordon,et al. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] B. Clotet,et al. Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity , 2016, BioMed research international.
[11] K. Suresh,et al. Tenofovir-induced nephrotoxicity: A retrospective cohort study. , 2016, The Medical journal of Malaysia.
[12] John F. Flaherty,et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.
[13] J. Baeten,et al. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. , 2016, Journal of Infectious Diseases.
[14] M. Buti,et al. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study , 2016, Journal of clinical gastroenterology.
[15] F. Palella,et al. Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men , 2016, Journal of acquired immune deficiency syndromes.
[16] B. Mâsse,et al. PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials , 2016, Journal of acquired immune deficiency syndromes.
[17] B. Kearney,et al. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment , 2016, Antimicrobial Agents and Chemotherapy.
[18] K. Tashima,et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results , 2016, Journal of acquired immune deficiency syndromes.
[19] J. Baeten,et al. Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. , 2016, Journal of acquired immune deficiency syndromes.
[20] J. Baeten,et al. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis , 2016, Journal of acquired immune deficiency syndromes.
[21] K. Lichtenstein,et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study , 2016, Journal of acquired immune deficiency syndromes.
[22] Abdur Rahman Khan,et al. Fanconi Syndrome and Antiretrovirals: It Is Never Too Late , 2016, American journal of therapeutics.
[23] J. Baeten,et al. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention , 2016, Expert opinion on drug safety.
[24] F. Liaño,et al. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir , 2016, AIDS.
[25] F. Palella,et al. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] J. van Lunzen,et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. , 2016, The Lancet. Infectious diseases.
[27] C. B. Hare,et al. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] D. Podzamczer,et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.
[29] Jimena García,et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients , 2015, International Journal of Clinical Pharmacy.
[30] D. Glidden,et al. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] A. Mocroft,et al. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study , 2015, PLoS medicine.
[32] J. Baeten,et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. , 2015, JAMA internal medicine.
[33] T. Santantonio,et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. , 2014, The Journal of antimicrobial chemotherapy.
[34] M. Buti,et al. Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.
[35] P. Lampertico,et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[36] P. Sax,et al. Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine , 2014, Journal of acquired immune deficiency syndromes.
[37] M. Shlipak,et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans , 2014, AIDS.
[38] R. Ebrahimi,et al. Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients , 2014, PloS one.
[39] A. Kosaka,et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat , 2014, Kidney international.
[40] D. Glidden,et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis , 2014, AIDS.
[41] P. Snelling,et al. Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B Monoinfection , 2013, Antiviral therapy.
[42] U. Bredeek,et al. Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.
[43] C. Hendrix,et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.
[44] K. Squires,et al. Bone Health and Human Immunodeficiency Virus Infection , 2013, Pharmacotherapy.
[45] P. Pang,et al. Randomized, placebo‐controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B , 2012, Hepatology.
[46] M. Shlipak,et al. Association of tenofovir exposure with kidney disease risk in HIV infection , 2012, AIDS.
[47] J. Stockman,et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men , 2012 .
[48] B. Hendry,et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[49] S. Hosseini,et al. Tenofovir Renal Proximal Tubular Toxicity Is Regulated By OAT1 and MRP4 Transporters , 2011, Laboratory Investigation.
[50] V. D’Agati,et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. , 2010, Kidney international.
[51] U. Walker,et al. Mitochondrial Tubulopathy in Tenofovir Disoproxil Fumarate-Treated Rats , 2009, Journal of acquired immune deficiency syndromes.
[52] V. Soriano,et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] Huy Trinh,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.
[54] B. Gazzard,et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.
[55] G. Braden,et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.